What is the treatment for radiation pneumonitis (inflammation of the lungs due to radiation therapy)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Radiation pneumonitis is best treated with corticosteroids, with prednisone being the first-line therapy at a dose of 1 mg/kg/day (typically 60-100 mg daily) for 2-4 weeks, followed by a slow taper over 6-12 weeks, as recommended by the most recent and highest quality study 1. The treatment of radiation pneumonitis involves a multi-faceted approach, including symptomatic treatment, anti-inflammatory drugs, and treatment of comorbid diseases.

  • Symptomatic treatment includes inhaled b2-mimetics and oxygen supplementation for patients with hypoxemia and dyspnea.
  • Anti-inflammatory drugs, such as corticosteroids, are used to reduce the inflammatory response triggered by radiation damage to lung tissue, with a moderate to high dose and tapered over several weeks 1.
  • Treatment of comorbid diseases is also essential to improve patient outcomes. The use of corticosteroids, such as prednisone, is supported by multiple studies, including a study published in the Annals of Oncology 1 and a study published in Chest 1, which recommend the use of corticosteroids for the treatment of radiation pneumonitis. Additionally, a study published in the Journal of Thoracic Oncology 1 suggests that patients with grade 2 pneumonitis should quickly begin a course of corticosteroids, starting at a minimum dose of 40 mg of prednisone daily and tapered over 8 to 10 weeks. However, the most recent and highest quality study 1 provides the most up-to-date guidance on the treatment of radiation pneumonitis, and its recommendations should be prioritized. Overall, the treatment of radiation pneumonitis requires a comprehensive approach that includes symptomatic treatment, anti-inflammatory drugs, and treatment of comorbid diseases, with corticosteroids being the first-line therapy.

From the Research

Radiation Pneumonitis Treatment Overview

  • Radiation pneumonitis (RP) is a dose-limiting toxicity for patients undergoing radiotherapy (RT) for lung cancer, and its optimal treatment remains unclear 2.
  • The treatment of RP should be multidisciplinary, and risk stratification is important, especially in the scenario of interstitial lung disease 2.

Treatment Options

  • For uncomplicated radiation pneumonitis, an equivalent to 60 mg oral prednisone per day, with consideration of gastroprotection, is a typical initial regimen 2.
  • The initial steroid dose should be administered for a duration of 2 weeks, followed by a gradual, weekly taper (equivalent to 10 mg prednisone decrease per week) 2.
  • For severe pneumonitis, IV methylprednisolone is recommended for 3 days prior to initiating oral corticosteroids 2.
  • Inhalative steroids can be used as an individual treatment option for radiation-induced pneumonitis grade II in patients with a good performance status 3.

Diagnosis and Management

  • Diagnoses are made by exclusion using clinical assessment and radiological findings 4.
  • Pulmonary function tests have constituted a significant step in evaluating lung function status during radiotherapy and useful predictive tools to avoid complications or limit toxicity 4.
  • Systemic corticosteroids are widely used to treat pneumonitis complications, but its use must be standardized, and consider in the prophylaxis setting given the fatal outcome of this adverse event 4.

Risk Factors and Predictors

  • Pre-treatment pulmonary function test and dose volume statistics were not predictive of RP requiring steroid intake after stereotactic irradiation for stage I NSCLC 5.
  • The potential biomarkers that predict the risk, and mitigators of radiation pneumonitis are being researched 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.